Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc.

Last Close

1.65

02/05 20:00

Market Cap

445.76M

Beta: 1.33

Volume Today

4.43M

Avg: 593.73K

PE Ratio

−3.21

PFCF: −3.75

Filings Not Available